Jan Beyersmann

Kaspar Rufibach, an expert in survival analysis and member of the SAVVY collaboration, and Jan Beyersmann, a professor of biostatistics at Ulm University, discuss the complexities of analyzing adverse events in clinical trials. They highlight how varying follow-up times can bias results and advocate for using the Aalen–Johansen estimator as a standard practice. The conversation emphasizes the successful collaboration between pharma and academia, revealing how real-world data can change the perception of treatment risks and enhance benefit-risk evaluations.